Printer Friendly

GARNIER ELECTED TO SMITHKLINE BEECHAM BOARD

 GARNIER ELECTED TO SMITHKLINE BEECHAM BOARD
 PHILADELPHIA, Sept. 29 /PRNewswire/ -- Dr. Jean-Pierre Garnier,


president - North America Pharmaceuticals, has been elected to the board of directors of SmithKline Beecham (NYSE: SBH), it was announced today.
 Garnier, 44, joined SmithKline Beecham in his present position in 1990. Prior to that he served as president of the U.S. pharmaceutical business at the Schering-Plough Corporation. He has worked in the pharmaceutical industry for 17 years.
 Born in France, Garnier received his Ph.D. in pharmacology from the University of Louis Pasteur and his master's in business administration from Stanford University in California, where he was a Fulbright Fellow.
 At the same time, it was announced that Francis P. Lucier has resigned as a member of the SmithKline Beecham board. Lucier, 65, who formerly was chairman of the board and chief executive officer of Black & Decker Manufacturing Company, had served on the company's and its predecessor's board since 1980.
 "The retirement of Frank marks the end of a long association with this company during a period of many changes," said SmithKline Beecham Board Chairman Henry Wendt. "I would like to thank him on behalf of the company for all his support and wish him a long and happy retirement."
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines and clinical laboratory testing services.
 /delval/
 -0- 9/29/92
 /CONTACT: Jeremy Heymsfeld of SmithKline Beecham, 215-751-5166/
 (SBH) CO: SmithKline Beecham ST: Pennsylvania IN: MTC SU: PER


MK -- PH007 -- 4226 09/29/92 08:59 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 29, 1992
Words:261
Previous Article:DRAMATIC TIME-TO-MARKET IMPROVEMENTS RESULT FROM TEXAS INSTRUMENTS' REUSABLE ENGINEERING APPROACH; COMPREHENSIVE MODULAR
Next Article:LOWE'S ANNOUNCES WEEKLY SALES
Topics:


Related Articles
GROOME NAMED TO LEAD SMITHKLINE BEECHAM'S CONSUMER BRANDS BUSINESS; HUNTER TO RETIRE
GROOME ELECTED TO SMITHKLINE BEECHAM BOARD
CEPHALON, INC. APPOINTS MARTYN D. GREENACRE TO NEW BOARD SEAT
ALAIN GOMEZ RESIGNS FROM SMITHKLINE BEECHAM BOARD OF DIRECTORS
SIR CHRISTOPHER HOGG ELECTED TO SMITHKLINE BEECHAM BOARD OF DIRECTORS
SIR PETER WALTERS NAMED SMITHKLINE BEECHAM CHAIRMAN JAN LESCHLY BECOMES CHIEF EXECUTIVE HENRY WENDT AND ROBERT BAUMAN RETIRE AT ANNUAL GENERAL MEETING
JP GARNIER APPOINTED CHIEF OPERATING OFFICER OF SMITHKLINE BEECHAM; KEY STEP IN HEALTHCARE INTEGRATION
SMITHKLINE BEECHAM STRENGTHENS COMMITMENT TO INTEGRATED HEALTHCARE; CREATES SB HEALTHCARE SERVICES UNIT TO BE HEADED BY DR. TADATAKA YAMADA,...
SmithKline Beecham Names George Poste Chief Science and Technology Officer
SmithKline Beecham Appoints Dr. David C. U'Prichard Chairman, Research And Development, Pharmaceuticals

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters